A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Injection in Patients with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type
Cancer - Mycosis Fungoides,
Cancer - Non-Hodgkin's Lymphoma
Lauren C Pinter-Brown
For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email email@example.com.